Data / Drug companies / Padagis US LLC
Padagis US LLC: 64 products in the FDA NDC directory, labeler code 0574
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Padagis US LLC (labeler code 0574) lists 64 products in the FDA National Drug Code Directory, covering 35 finished drugs by generic name. By type: 60 prescription drugs, 4 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 28, 2026.
The request: Watch Padagis US LLC (FDA labeler code 0574): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0574
- Products in commercial distribution
- 64
- Packages
- 93
- Finished drugs by generic name
- 35
- Prescription products
- 60
- Over the counter products
- 4
- Controlled substance products
- Schedule II 15, Schedule III 2, Schedule IV 1
- Flagged as original packager
- 63 of 63 products that carry the flag
- Started marketing in the last 12 months
- 10
- Products with a marketing end date set
- 5
- Earliest marketing start
- July 1, 1990
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 38 | 59.4% |
| Other unapproved drugs | 11 | 17.2% |
| Authorized generics (NDA) | 10 | 15.6% |
| Over the counter monograph drugs | 3 | 4.7% |
| New drug applications (NDA) | 2 | 3.1% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 60 | 93.8% |
| Over the counter drugs | 4 | 6.2% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Suppository | 12 | 18.8% |
| Capsule | 8 | 12.5% |
| Tablet | 7 | 10.9% |
| Cream | 4 | 6.2% |
| Gel | 4 | 6.2% |
| Tablet, extended release | 4 | 6.2% |
| Patch | 4 | 6.2% |
| Suspension/ drops | 4 | 6.2% |
| Suspension | 3 | 4.7% |
| Injection, solution | 2 | 3.1% |
| Syrup | 2 | 3.1% |
| Tablet, film coated | 2 | 3.1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Phytonadione | 0574-1850 | Tablet | Generic drugs (ANDA) | October 28, 2026 |
| Tofacitinib citrate | 0574-1811 | Tablet, film coated, extended release | Generic drugs (ANDA) | June 15, 2026 |
| Loteprednol etabonate | 0574-4080 | Suspension/ drops | Generic drugs (ANDA) | March 31, 2026 |
| Lenalidomide | 0574-1425 | Capsule | Generic drugs (ANDA) | January 31, 2026 |
| Lenalidomide | 0574-1420 | Capsule | Generic drugs (ANDA) | January 31, 2026 |
| Lenalidomide | 0574-1415 | Capsule | Generic drugs (ANDA) | January 31, 2026 |
| Lenalidomide | 0574-1410 | Capsule | Generic drugs (ANDA) | January 31, 2026 |
| Lenalidomide | 0574-1405 | Capsule | Generic drugs (ANDA) | January 31, 2026 |
| Lenalidomide | 0574-1402 | Capsule | Generic drugs (ANDA) | January 31, 2026 |
| Loteprednol etabonate | 0574-4135 | Suspension/ drops | Generic drugs (ANDA) | January 12, 2026 |
| Podofilox | 0574-0621 | Gel | Generic drugs (ANDA) | December 13, 2023 |
| Spironolactone | 0574-1133 | Suspension | Authorized generics (NDA) | October 31, 2023 |
| Brinzolamide | 0574-4012 | Suspension/ drops | Generic drugs (ANDA) | October 10, 2023 |
| Methylphenidate Transdermal System | 0574-2430 | Patch | Authorized generics (NDA) | June 5, 2023 |
| Methylphenidate Transdermal System | 0574-2420 | Patch | Authorized generics (NDA) | June 5, 2023 |
| Methylphenidate Transdermal System | 0574-2415 | Patch | Authorized generics (NDA) | June 5, 2023 |
| Methylphenidate Transdermal System | 0574-2410 | Patch | Authorized generics (NDA) | June 5, 2023 |
| Lidocaine and prilocaine | 0574-2042 | Cream | Generic drugs (ANDA) | December 20, 2022 |
| Tobramycin and dexamethasone | 0574-4031 | Suspension/ drops | Generic drugs (ANDA) | March 17, 2022 |
| Actidose | 0574-0520 | Suspension | Over the counter monograph drugs | December 5, 2020 |
| Actidose aqua | 0574-0521 | Suspension | Over the counter monograph drugs | November 10, 2020 |
| Benazepril hydrochloride and hydrochlorothiazide | 0574-0229 | Tablet | Authorized generics (NDA) | April 7, 2019 |
| Benazepril hydrochloride and hydrochlorothiazide | 0574-0228 | Tablet | Authorized generics (NDA) | April 7, 2019 |
| Budesonide | 0574-9855 | Capsule | New drug applications (NDA) | June 29, 2018 |
| Paroxetine | 0574-0279 | Capsule | Authorized generics (NDA) | October 3, 2017 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.